Vistagen Therapeutics, Inc.
Vistagen Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on neuroscience disorders. Its pipeline centers on pherine product candidates, including intranasal therapies being developed for anxiety, depression, and other central nervous system indications.
Tilikausi 2026 · muutos edellisvuodesta
Kehitys 2021–2026
Liiketoiminta
Osuus liikevaihdostaIntranasal neuroscience drug candidates designed to treat anxiety, mood, and related disorders.
Revenue recognized from collaboration, sublicense, and related contractual arrangements.
Asiakkaat
Vistagen does not yet sell approved commercial products; its economic counterparties are primarily licensing partners, research collaborators, CROs, CDMOs, and clinical trial sites. If approved, its end customers would be patients treated by physicians in psychiatry, neurology, women’s health, and other specialty care settings.
Buy or license development rights and support commercialization through strategic agreements.
Provide outsourced development, testing, and manufacturing capacity that enables the pipeline.
Run the studies needed to generate safety and efficacy data for regulatory approval.
Future end users of approved therapies for social anxiety, depression, and related disorders.
Strategia
The company’s strategy is to advance its lead pherine candidates through clinical development and regulatory review, with fasedienol as the most advanced program. It also seeks partnerships and non-dilutive funding where possible while building the manufacturing and supply chain capabilities needed for eventual commercialization.
It is the lead asset and the most direct path to a first commercial product.
A broader portfolio reduces dependence on a single indication and expands future market opportunities.
Clinical and future commercial execution depend on reliable manufacturing and backup sourcing.
Maantiede
Vistagen is headquartered in the United States and operates from South San Francisco, California. Its development and manufacturing network is U.S.-centered, but the company also contemplates backup manufacturing and future supply arrangements outside the U.S. for approved products.
Riskit
Vistagen is exposed to the typical risks of clinical-stage drug development: trial failure, regulatory delay, manufacturing complexity, and competition from larger pharmaceutical companies. Because it has not yet commercialized a product, its business depends heavily on successful clinical outcomes, access to capital, and protection of its intellectual property.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
Product candidates may not demonstrate sufficient efficacy or tolerability in trials.
Kohdistuu - Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
FDA or other regulators may require additional data or reject applications.
Kohdistuu: Late-stage neuroscience programs
- Funding riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company expects existing resources to be insufficient beyond the near term.
Kohdistuu: Ongoing R&D and pre-commercial activities
- Competitive intensityVaikutus: KorkeaTodennäköisyys: Kohtalainen
Large pharma and biotech firms have greater resources and established commercial reach.
Kohdistuu - Manufacturing and supply chain executionVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Commercial supply depends on CDMOs and future backup manufacturing arrangements.
Kohdistuu: Future approved pherine products
Kirjanpito
Harkinnanvaraiset erätClinical and manufacturing vendors bill on timing that may differ from work performed, requiring estimates.
Vaikutus: Can shift expenses between periods and affect reported operating loss
Revenue is recognized as performance obligations are satisfied under collaboration agreements.
Vaikutus: Can create uneven quarterly revenue recognition
The company leases office and laboratory space in South San Francisco.
Vaikutus: Affects right-of-use assets, lease liabilities, and fixed commitments
Commercial supply agreements with CDMOs may create contractual commitments.
Vaikutus: Could increase future liabilities and cash requirements
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Neurogene Inc.
NGNE · Pharmaceutical Preparations
Pasithea Therapeutics Corp.
KTTA · Pharmaceutical Preparations
Edgewise Therapeutics, Inc.
EWTX · Pharmaceutical Preparations
Cadrenal Therapeutics, Inc.
CVKD · Pharmaceutical Preparations
Vera Therapeutics, Inc.
VERA · Pharmaceutical Preparations
vTv Therapeutics Inc.
VTVT · Pharmaceutical Preparations
Päivitetty: 24.9.2026